Earnings call transcript: Ameris Bancorp tops Q3 2026 EPS forecast

Ameris Bancorp reported Q3 2026 diluted EPS of $1.73, beating the $1.68 estimate and reaching a five-year high, while revenue of $321.85 million fell $4.95 million short of forecasts. Net interest margin was nearly stable at 387 basis points, and the board approved a new $200 million share-repurchase authorization; the stock was little changed, up 0.16% to $82.50. Management expects mid-single-digit loan and deposit growth but cautioned that rising deposit costs could cause margin pressure and volatility over the next few quarters.

Analysis

ABCB’s edge is not simply loan growth; it is whether relationship deposits keep that growth from becoming margin-dilutive. Management’s own spread math implies interest-bearing funding alone would not support current loan-production economics, so deposit mix and pricing—not reported EPS—are the key next-quarter tells. A small spot-cost uptick alongside stronger asset yields is encouraging, but does not establish that the post-hike deposit repricing cycle is complete. If depositors migrate from non-interest-bearing balances or competitors bid up rates, incremental volume could dilute returns even while reported balances grow.

Near term, the buyback authorization is optionality, not a bid: capital deployment remains subordinate to organic growth, and no repurchases occurred this quarter. Mortgage weakness may be partly offset by expense flexibility, but a rate-driven volume rebound could also require costs to rise; treat operating leverage there as unproven. Over 6–18 months, disciplined pricing and deposit-led expansion matter more than headline growth. CRE payoffs can improve replacement yields while also constraining earning-asset growth; rising criticized/classified assets merit monitoring despite management’s benign loss outlook.

The contrarian point: the modest EPS beat is less informative than whether ABCB refuses uneconomic loan pricing. There is no strong basis here to chase the shares after a muted reaction, and the article’s valuation claims lack enough supporting detail for a rerating call. A relative long versus KRE is only a conditional setup, not a current conviction trade.

Key Decisions for Investors

• No immediate directional trade: keep ABCB on watch rather than buy the earnings beat. Reassess after the next quarter’s deposit-cost, non-interest-bearing mix, and NIM disclosures.
• Conditional relative-value idea: consider a small long ABCB / short KRE position only if deposit costs stabilize while loan yields and core-deposit growth hold up; verify peer valuation and deposit-beta data first. Exit or stand aside if NIM compression persists or deposit mix deteriorates.
• Treat the $200 million authorization as non-binding. Look for actual repurchase activity and compare it with organic loan growth and tangible-book-value accretion before assigning buyback support to the shares.
• Thesis falsifiers: consecutive quarters of margin compression driven by funding costs, loan growth requiring materially more expensive deposits, or worsening credit migration/charge-offs beyond management’s near-term outlook.